Ravi Chari Email Address

Biotechnology Consultant

Learn more about Immunogen's ADC technology used in Roche's Kadcyla(r), changing the lives of people with cancer.

I have considerable experience in cancer drug discovery. Most of my career has been devoted to developing targeted therapies for cancer, specifically Antibody-Drug Conjugates (ADCs), to provide effective, but less toxic options to the patient. I started off as a bench chemist, and during my 30+ years as a cancer researcher, I have been involved in numerous aspects of cancer drug development, starting with conception of an idea to bench chemistry, and lead optimization. Subsequently, I guided preclinical research to identify a clinical candidate, and then facilitated technology transfer for scale up synthesis for clinical trials. The culmination of one of my efforts was the FDA approval of the cancer drug Kadcyla for the treatment of breast cancer. I am one of the two inventors on the issued U.S. Patent 8,337,856 that covers the “composition of matter” of this drug. My research work on ADCs as therapeutic agents for cancer, specifically has resulted in 102 issued U.S. Patents, wherein I am the named inventor, and >60 peer-reviewed publications in top scientific journals. I can be of help to you in multiple aspects of cancer drug development, including ADCs (design and evaluation) medicinal chemistry, lead identification, protein biochemistry, patents (including proactive filings, and responses to office actions). If your focus is ADCs, I can provide valuable insight into mechanism of action, and optimal antibody, linker and drug properties. I can also assist you in technology evaluation